mRNA-1273疫苗接种后对SARS-CoV-2奥密克戎BA.2.75的中和作用。 - Suppr

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

作者信息

Shen Xiaoying, Chalkias Spyros, Feng Jing, Chen Xing, Zhou Honghong, Marshall Jean-Claude, Girard Bethany, Tomassini Joanne E, Aunins Anne, Das Rituparna, Montefiori David C

机构信息

Duke University Medical Center, Durham, NC.

Moderna, Cambridge, MA.

出版信息

N Engl J Med. 2022 Sep 29;387(13):1234-1236. doi: 10.1056/NEJMc2210648. Epub 2022 Sep 9.

DOI:10.1056/NEJMc2210648

PMID:36083119

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9511611/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f57/9511611/9b4e77f27e5d/NEJMc2210648_f1.jpg

相似文献

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

N Engl J Med. 2022 Sep 29;387(13):1234-1236. doi: 10.1056/NEJMc2210648. Epub 2022 Sep 9.

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.

Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31.

Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.

Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.

Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.

EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.

Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.

Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.

EBioMedicine. 2021 Dec;74:103748. doi: 10.1016/j.ebiom.2021.103748. Epub 2021 Dec 10.

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination.

Infection. 2023 Apr;51(2):531-534. doi: 10.1007/s15010-022-01922-8. Epub 2022 Sep 15.

Audio Interview: A Look at Covid-19 Prevention and Care in 2020.

N Engl J Med. 2020 Dec 31;383(27):e147. doi: 10.1056/NEJMe2036225.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.

N Engl J Med. 2022 Apr 21;386(16):1579-1580. doi: 10.1056/NEJMc2201849. Epub 2022 Mar 16.

引用本文的文献

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.

Nat Commun. 2024 Aug 29;15(1):7469. doi: 10.1038/s41467-024-50376-z.

Temporal Dynamics and Genomic Landscape of SARS-CoV-2 After Four Years of Evolution.

Cureus. 2024 Feb 5;16(2):e53654. doi: 10.7759/cureus.53654. eCollection 2024 Feb.

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

Nat Commun. 2023 Aug 23;14(1):5125. doi: 10.1038/s41467-023-38892-w.

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z.

Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.

Clin Exp Nephrol. 2023 Aug;27(8):660-671. doi: 10.1007/s10157-023-02348-8. Epub 2023 Apr 24.

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.

Clin Infect Dis. 2023 Aug 22;77(4):560-564. doi: 10.1093/cid/ciad209.

Durability of immune responses to mRNA booster vaccination against COVID-19.

J Clin Invest. 2023 May 15;133(10):e167955. doi: 10.1172/JCI167955.

Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.

Cytokine Growth Factor Rev. 2023 Apr;70:13-25. doi: 10.1016/j.cytogfr.2023.03.001. Epub 2023 Mar 5.

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.

Cell Rep. 2023 Jan 31;42(1):111998. doi: 10.1016/j.celrep.2023.111998. Epub 2023 Jan 9.

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages.

Int J Med Sci. 2023 Jan 1;20(1):151-162. doi: 10.7150/ijms.79116. eCollection 2023.

本文引用的文献

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.

Vaccine. 2021 May 12;39(20):2791-2799. doi: 10.1016/j.vaccine.2021.02.007. Epub 2021 Feb 9.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.

Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献